Skip to main content
Back to feed
HealthSingle-sourceLow
2.1

Egetis Therapeutics receives orphan drug designation for Emcitate in Japan

Egetis Therapeutics, via partner Fujimoto Pharmaceutical, secured orphan drug designation for tiratricol in Japan. This regulatory milestone facilitates the potential commercialization of the treatment for MCT8 deficiency in the Japanese market.

Dagens Industri2 days agoJP, SECredibility 27%View source

Score Breakdown

Mosaic Score2.1
Confidence0.9
Significance0.1
Source credibility0.3

Intelligence Tags

#pharmaceuticals#orphan-drug#regulatory-approval#biotech

Locations

Japan

Entities

countrycountry
Source

Related signals

8 found